NOTICE! LECTURE TIMES ARE SET ACCORDING TO GMT+2 TIME ZONE (Warsaw, Poland)
Use the timezone converter to easily convert to your time GO TO CONVERTER
Use the timezone converter to easily convert to your time GO TO CONVERTER
20
April
Wednesday
11:45
- 14:10
11:45
- 12:10
Lowering cancer risk in patients with inherited predisposition by optimizing dietary parameters
Lecturer
Jan Lubiński
12:10
- 12:35
Hereditary factors of ovarian cancers
Lecturer
12:35
- 13:00
Clinics of breast cancers in carriers of CHEK2 mutations
Lecturer
Cezary Cybulski
13:00
- 13:25
Lead blood level as marker of cancer risk
Lecturer
Sandra Pietrzak
13:25
- 13:50
Serum selenium level as marker of survival in patients with malignant melanoma
Lecturer
Tadeusz Dębniak
13:50
- 14:10
DISCUSSION
14:10
- 14:20
BREAK
14:20
- 17:05
14:20
- 14:45
Tumor oximetry and hypoxia modification in preclinical model
Lecturer
Martyna Elas
14:45
- 15:10
Adjuvant therapy based on tumor microenvironment conditions
Lecturer
Claudine Kieda
15:10
- 15:35
Evaluation of microheterogeneity of microenvironment in daily pathological practice
Lecturer
Andrzej Marszałek
15:35
- 16:00
Intratumor heterogeneity assessed by mass spectrometry imaging and cancer prognosis
Lecturer
Piotr Widłak
16:00
- 16:25
Immunosuppression in tumor microenvironment and its targeting
Lecturer
Viktor Umansky
Heidelberg, GER
16:25
- 17:05
DISCUSSION
17:05
- 17:15
BREAK
17:15
- 19:30
SESSION 3. Immunomodulation
Chair:
Lecturers
Danuta Kozbor-Fogelberg
Salem Chouaib
17:15
- 18:10
Reprograming responsiveness of tolerogenic CD8+ T cells by oncolytic virotherapy with CXCR4-antagonist is associated with reversing M2 macrophage polarization
Lecturer
Danuta Kozbor-Fogelberg
18:10
- 18:45
The turbulent hypoxia-anti-tumor immune response relationship
Lecturer
Salem Chouaib
18:45
- 19:10
Dendritic cell-targeting therapies of cancer
Lecturer
19:10
- 19:30
DISCUSSION
19:30
- 19:40
BREAK
19:40
- 19:50
WELCOME ADDRESS
Lecturer
Andrzej Mackiewicz
19:50
- 20:20
Keynote lecture:
Interleukin-6 at the host-tumor interface: STAT3 in biomolecular condensates in cancer cells
Interleukin-6 at the host-tumor interface: STAT3 in biomolecular condensates in cancer cells
Lecturer
Pravin Sehgal
20:20
- 20:50
Keynote lecture:
Myeloma 2022 - Main Challenges and Path Forward
Myeloma 2022 - Main Challenges and Path Forward
Lecturer
21
April
Thursday
12:15
- 15:05
SESSION 4. Cancer targeting
Chair:
Lecturers
Hanna Rokita
Cracow, PL
Lidia Gil
12:15
- 12:40
Proteomic profile of melanoma cell-drived small extracellular vesicles correlate of melanoma progression
Lecturer
Monika Pietrowska
12:40
- 13:05
Cancer stemness and proteogenomics for target identification
Lecturer
Maciej Wiznerowicz
13:05
- 13:30
Targeting GD2 ganglioside in neuroblastoma induces PHLDA1 and modulates cell metabolism
Lecturer
Hanna Rokita
Cracow, PL
13:30
- 13:55
Organotropic Approach to Novel Anticancer Therapies
Lecturer
13:55
- 14:20
CAR T-cell therapy in ALL - where are we in 2022
Lecturer
Lidia Gil
14:20
- 14:45
Boosting GvL by direct exposure of donor lymphocytes to leukemic cells at relapse employing intra-bone route
Lecturer
Andrzej Lange
14:45
- 15:05
DISCUSSION
15:05
- 15:15
BREAK
15:15
- 17:10
15:15
- 15:40
Blocking Key Steps in Inflammation and Cancer
Lecturer
Stefan Rose-John
15:40
- 16:05
Small Extracellular Vesicles (sEVs) in cancer plasma as contributors to liquid tumor biopsy
Lecturer
Theresa Whiteside
16:05
- 16:30
Circulating Tumour Cells (CTC): do we have a new risk assessment marker in the progression of oligometastatic disease?
Lecturer
16:30
- 16:55
Diagnostic and predictive value of circulating melanoma cells in patients treated with immunotherapy
Łukasz Galus, Karolina
Buszka, Anna Szoszkiewicz, Mariusz Kaczmarek, Michał Nowicki, Jacek Mackiewicz,
Joanna Budna-Tukan
Lecturer
Paula Kamińska
Poznań, PL
16:55
- 17:10
DISCUSSION
17:10
- 17:20
BREAK
17:20
- 20:10
17:20
- 17:45
Breast cancer- dissimilarity between male and female tumors.
Lecturer
Piotr Czapiewski
Germany
17:45
- 18:10
Methylation profile of ovarian tumors
Lecturers
Laura Szafron
18:10
- 18:35
RNA editing in cancer
Lecturer
Małgorzata Kurkowiak
18:35
- 19:00
IGHV-associated methylation signatures more accurately predict clinical outcomes of chronic lymphocytic leukemia patients than IGHV mutation load
Lecturer
Tomasz K. Wojdacz
19:00
- 19:25
Profile of peripheral blood NK cells in melanoma patients treated with immune checkpoint inhibitors
Katarzyna Tomela, Łukasz Galus, Bernadeta Pietrzak, Marcin Schmidt, Jacek Mackiewicz, Andrzej Mackiewicz
Lecturer
Mariusz Kaczmarek
19:25
- 19:50
Gut microbial and metabolic profiles associated with response to treatment with PD1/PD-L1 blockade therapy in metastatic melanoma
Artur Szwengiel, Bernadeta Pietrzak, Katarzyna Tomela, Łukasz Galus, Agnieszka Olejnik-Schmidt, Mariusz Kaczmarek, Jacek Mackiewicz, Andrzej Mackiewicz
Lecturer
Marcin Schmidt
Poznań, PL
19:50
- 20:10
DISCUSSION
22
April
Friday
13:30
- 15:20
SESSION 7: Postępy w leczeniu chorych na raka jelita grubego
Advances in the treatment of patients with colorectal cancer
Advances in the treatment of patients with colorectal cancer
Chair:
Lecturers
Barbara Radecka
Piotr Milecki
13:30
- 13:50
Zalety i wady laparoskopii u chorych na raka jelita grubego
Advantages and disadvantages of laparoscopy in patients with colorectal cancer
Advantages and disadvantages of laparoscopy in patients with colorectal cancer
Lecturer
Tomasz Banasiewicz
13:50
- 14:10
Postępy w leczeniu chirurgicznym przerzutów do wątroby
Advances in the surgical treatment of liver metastases
Advances in the surgical treatment of liver metastases
Lecturer
Dawid Murawa
14:10
- 14:30
Postępy w radioterapii u chorych na raka odbytnicy
Advances in radiotherapy in patients with rectal cancer
Advances in radiotherapy in patients with rectal cancer
Lecturer
Piotr Milecki
14:30
- 14:50
Postępy w terapii celowanej u chorych na raka jelita grubego
Advances in targeted therapy in patients with colorectal cancer
Advances in targeted therapy in patients with colorectal cancer
Lecturer
Rafał Stec
Warsaw, PL
14:50
- 15:10
Miejsce immunoterapii w leczeniu chorych na nowotwory jelita grubego MSI-H
The place of immunotherapy in the treatment of patients (MSI-H) colorectal cancer
The place of immunotherapy in the treatment of patients (MSI-H) colorectal cancer
Wykład sponsorowany / Sponsored lecture
Lecturer
Barbara Radecka
15:10
- 15:20
DISCUSSION
15:20
- 15:30
BREAK
15:30
- 17:45
SESSION 8: Postępy w leczeniu chorych na czerniaka
Advances in the treatment of patients with melanoma
Advances in the treatment of patients with melanoma
Chair:
Lecturers
Piotr Rutkowski
Warsaw, PL
Jacek Mackiewicz
15:30
- 15:50
Nowe trendy w diagnostyce czerniaków skóry
New trends in the diagnosis of skin melanomas
New trends in the diagnosis of skin melanomas
Lecturer
Jacek Calik
15:50
- 16:10
Jak poprawić skuteczność leczenia u chorych na czerniaka
How to improve the effectiveness of treatment in patients with melanoma
How to improve the effectiveness of treatment in patients with melanoma
Wykład pod patronatem
Lecturer
Jacek Mackiewicz
16:10
- 16:30
Co nowego, a co bez zmian w chirurgicznym leczeniu chorych na czerniaka?
What's new, and what's the same in the surgical treatment of melanoma patients?
What's new, and what's the same in the surgical treatment of melanoma patients?
Lecturer
Wojciech M. Wysocki
16:30
- 16:50
Leczenie okołooperacyjne u chorych na czerniaka
Perioperative treatment in patients with melanoma
Perioperative treatment in patients with melanoma
Wykład sponsorowany / Sponsored lecture
Lecturer
Piotr Rutkowski
Warsaw, PL
16:50
- 17:10
Kryteria doboru immunoterapii u chorych na uogólnionego czerniaka
Criteria for selecting immunotherapy in patients with metastatic melanoma
Criteria for selecting immunotherapy in patients with metastatic melanoma
Wykład sponsorowany / Sponsored lecture
Lecturer
Bożena Cybulska-Stopa
17:10
- 17:30
Miejsce terapii celowanej u chorych na uogólnionego czerniaka
The place of targeted therapy in patients with metastatic melanoma
The place of targeted therapy in patients with metastatic melanoma
Lecturer
Anna Czarnecka
17:30
- 17:45
DISCUSSION
17:45
- 17:55
BREAK
17:55
- 19:45
SESSION 9:
Targeted therapy in lympho- and myeloproliferative neoplasms: new concepts and new expectations
Targeted therapy in lympho- and myeloproliferative neoplasms: new concepts and new expectations
Chair:
Lecturers
Krzysztof Lewandowski
Grzegorz Przybylski
17:55
- 18:20
STAT and JAK gene mutations in lympho- and myeloproliferative disorders
Lecturer
Krzysztof Lewandowski
18:20
- 18:45
JAK-STAT pathways inhibitors in the treatment of myeloproliferative neoplasms
Lecturer
Marta Sobas
18:45
- 19:10
Novel targeted therapies of T cell lymphomas
Lecturer
Grzegorz Przybylski
19:10
- 19:35
1-line treatment of CLL/SLL: Targeted Therapy or Chemoimmunotherapy?
Lecturer
Krzysztof Jamroziak
19:35
- 19:45
DISCUSSION
23
April
Saturday
09:00
- 10:55
SESSION 10: Postępy w leczeniu chorych na raka płuca
Advances in the treatment of patients with lung cancer
Advances in the treatment of patients with lung cancer
Chair:
Lecturers
Rodryg Ramlau
Tadeusz Orłowski
09:00
- 09:20
Postępy w leczeniu chirurgicznym u chorych na raka płuca
Advances in surgical treatment in lung cancer patients
Advances in surgical treatment in lung cancer patients
Lecturer
Tadeusz Orłowski
09:20
- 09:40
Postępy w leczeniu chorych na miejscowo zaawansowanego niedrobnokomórkowego raka płuca
Advances in the treatment of patients with locally advanced non-small cell lung cancer
Advances in the treatment of patients with locally advanced non-small cell lung cancer
Lecturer
Anna Wrona
09:40
- 10:00
Pierwsza linia leczenia u chorych na niedrobnokomórkowego raka płuca
The first line of treatment in patients with non-small cell lung cancer
The first line of treatment in patients with non-small cell lung cancer
Wykład pod patronatem
Lecturer
Adam Płużański
10:00
- 10:20
Immunoterapia skojarzona - w leczeniu chorych na niedrobnokomórkowego raka płuca
Combined immunotherapy - in the treatment of patients with non-small cell lung cancer
Combined immunotherapy - in the treatment of patients with non-small cell lung cancer
Wykład sponsorowany / Sponsored lecture
Lecturer
Rodryg Ramlau
10:20
- 10:40
Nowości w leczeniu chorych na drobnokomórkowego raka płuca
New solutions in the treatment of patients with small cell lung cancer
New solutions in the treatment of patients with small cell lung cancer
Lecturer
Katarzyna Stencel
10:40
- 10:55
DISCUSSION
10:55
- 11:05
BREAK
11:05
- 12:45
SESSION 11. Postępy w terapii systemowej u chorych na nowotwory złośliwe
Advances in the treatment of cancer patients
Advances in the treatment of cancer patients
Chair:
Lecturers
Piotr Tomczak
Wojciech Rogowski
11:05
- 11:25
Postępy w leczeniu systemowym u chorych na nowotwory głowy i szyi
Advances in systemic therapy in patients with head and neck cancer
Advances in systemic therapy in patients with head and neck cancer
Wykład pod patronatem
Lecturer
Izabela Łasińska
11:25
- 11:45
Postępy w leczeniu systemowym u chorych na zaawansowanego raka nerki
Advances in systemic treatment in patients with advanced kidney cancer
Advances in systemic treatment in patients with advanced kidney cancer
Wykład sponsorowany / Sponsored lecture
Lecturer
Piotr Tomczak
11:45
- 12:05
Postępy w immunoterapii górnego odcinka przewodu pokarmowego
Advances in immunotherapy of the upper gastrointestinal tract
Advances in immunotherapy of the upper gastrointestinal tract
Wykład sponsorowany / Sponsored lecture
Lecturer
Tomasz Kubiatowski
12:05
- 12:25
Leczenie podtrzymujące u chorych na raka pęcherza moczowego
Maintenance treatment in patients with bladder cancer
Maintenance treatment in patients with bladder cancer
Lecturer
Wojciech Rogowski
12:25
- 12:45
Leczenie kolczystokomórkowego (płaskonabłonkowego) raka skóry w oparciu o przypadki kliniczne
Treatment of squamous cell skin cancer based on clinical cases
Treatment of squamous cell skin cancer based on clinical cases
Lecturer
Hanna Koseła-Paterczyk
12:45
- 13:00
DISCUSSION
13:00
- 13:10
BREAK
13:10
- 14:15
SESSION 12. Presentations selected from Abstracts
Chair:
Lecturers
Andrzej Mackiewicz
Jacek Mackiewicz
13:10
- 13:20
Biological heterogeneity of primary cancer associated fibroblasts isolated from breast cancer tissue
Marika Musielak
Poznań, PL
13:20
- 13:30
A rare case of a neurological adverse event of immune checkpoint inhibitors - LIMBIC ENCEPHALITIS
Weronika Radecka
Opole, PL
13:30
- 13:40
miR-27b-5p: a short non-coding RNA with diagnostic potential in head and neck squamous cell carcinoma
Joanna Kozłowska-Masłoń
Poznań, PL
13:40
- 13:50
Chloride intracellular channels in head and neck squamous cell carcinoma
Bartosz Wojtera
Poznań, PL
13:50
- 14:30
DISCUSSION
CLOSING THE CONFERENCE